Mirtazapine Manx Healthcare

Mirtazapine, the active ingredient in Mirtazapine Manx Healthcare, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed to treat major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapine Manx Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Mirtazapine is a NaSSA antidepressant that acts on neurotransmitter pathways involved in mood regulation.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Depressive episodes associated with major depressive disorder: helps alleviate insomnia and loss of appetite. - Treatment‑resistant depression (adjunct therapy): may enhance response when combined with other antidepressants.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of sleepiness, especially after initiation. - Increased appetite and weight gain: heightened hunger leading to weight increase. - Dry mouth: reduced salivation causing oral discomfort. - Constipation: slowed gastrointestinal transit. - Dizziness: light‑headed sensation upon standing. - Fatigue: persistent lack of energy.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, increasing infection risk. - Seizures: rare occurrence of convulsive episodes. - Severe hypersensitivity reactions: rash, swelling, or anaphylaxis.

When prescribing Mirtazapine, clinicians should consider several safety precautions to minimize risk.

- Monitor weight: patients may experience significant weight gain. - Assess for suicidal thoughts: especially during early treatment or dose changes. - Evaluate liver function: use with caution in hepatic impairment. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Mirtazapine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedative effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase mirtazapine plasma levels. - Anticholinergic agents: additive dry mouth and constipation. - Other serotonergic drugs (e.g., SSRIs, tramadol): may raise risk of serotonin syndrome.